Head to Head Survey: Navidea Biopharmaceuticals (NYSE:NAVB) and Alpha Teknova (NASDAQ:TKNO)
Head to Head Survey: Navidea Biopharmaceuticals (NYSE:NAVB) and Alpha Teknova (NASDAQ:TKNO)
Alpha Teknova (NASDAQ:TKNO – Get Rating) and Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.
納斯達克：TKNO-GET評級公司和納維迪亞生物製藥公司(紐約證券交易所代碼：NAVB-GET評級)都是小盤醫療公司，但哪一家更好？我們將根據這兩家公司的機構所有權、分析師建議、盈利能力、估值、收益、風險和股息的實力進行比較。
Insider and Institutional Ownership
內部人與機構持股
24.6% of Alpha Teknova shares are held by institutional investors. Comparatively, 5.6% of Navidea Biopharmaceuticals shares are held by institutional investors. 15.2% of Alpha Teknova shares are held by company insiders. Comparatively, 32.4% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Alpha Tenowva 24.6%的股份由機構投資者持有。相比之下，Navidea BiopPharmticals 5.6%的股份由機構投資者持有。阿爾法公司15.2%的股份由公司內部人士持有。相比之下，Navidea BiopPharmticals 32.4%的股份由公司內部人士持有。強大的機構持股表明，對衝基金、大型基金管理公司和捐贈基金相信，一家公司的長期表現將好於大盤。
Risk & Volatility
風險與波動性
Alpha Teknova has a beta of -0.8, meaning that its share price is 180% less volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
Alpha Tenowva的貝塔係數為-0.8，這意味着其股價的波動性比標準普爾500指數低180%。相比之下，Navidea BiopPharmticals的貝塔係數為1.38，這意味着其股價的波動性比標準普爾500指數高38%。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Teknova | -43.93% | -13.25% | -10.60% |
| Navidea Biopharmaceuticals | -2,209.23% | -517.32% | -222.49% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 阿爾法·特克諾瓦 | -43.93% | -13.25% | -10.60% |
| Navidea生物製藥公司 | -2,209.23% | -517.32% | -222.49% |
Analyst Ratings
分析師評級
This is a summary of current ratings and recommmendations for Alpha Teknova and Navidea Biopharmaceuticals, as reported by MarketBeat.com.
據MarketBeat.com報道，這是對Alpha Tenowva和Navidea生物製藥公司當前評級和推薦的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Teknova | 0 | 0 | 2 | 0 | 3.00 |
| Navidea Biopharmaceuticals | 0 | 0 | 0 | 0 | N/A |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 阿爾法·特克諾瓦 | 0 | 0 | 2 | 0 | 3.00 |
| Navidea生物製藥公司 | 0 | 0 | 0 | 0 | 不適用 |
Alpha Teknova currently has a consensus price target of $22.50, indicating a potential upside of 416.06%. Given Alpha Teknova's higher probable upside, equities analysts clearly believe Alpha Teknova is more favorable than Navidea Biopharmaceuticals.
阿爾法·特克諾瓦目前的共識目標價為22.5美元，這表明潛在的上漲幅度為416.06。鑑於阿爾法·特諾瓦更有可能上行，股票分析師顯然認為阿爾法·特克諾瓦比Navidea BiopPharmticals更有利。
Valuation and Earnings
估值和收益
This table compares Alpha Teknova and Navidea Biopharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
該表格比較了Alpha Tenowva和Navidea生物製藥公司的營收、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Teknova | $36.89 million | 3.32 | -$9.80 million | ($0.67) | -6.51 |
| Navidea Biopharmaceuticals | $530,000.00 | 16.84 | -$11.73 million | ($0.40) | -0.73 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 阿爾法·特克諾瓦 | 3,689萬美元 | 3.32 | -980萬元 | ($0.67) | -6.51 |
| Navidea生物製藥公司 | $530,000.00 | 16.84 | -1,173萬元 | ($0.40) | -0.73 |
Alpha Teknova has higher revenue and earnings than Navidea Biopharmaceuticals. Alpha Teknova is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.
阿爾法·特克諾瓦的收入和收益高於Navidea生物製藥公司。Alpha Tenowva的市盈率低於Navidea BiopPharmticals，這表明它目前是兩隻股票中更負擔得起的一隻。
Summary
摘要
Alpha Teknova beats Navidea Biopharmaceuticals on 8 of the 13 factors compared between the two stocks.
阿爾法·特諾瓦在兩隻股票比較的13個因素中有8個擊敗了Navidea BiopPharmticals。
About Alpha Teknova
關於阿爾法·特克諾瓦
(Get Rating)
(獲取評級)
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
阿爾法·特諾瓦公司為美國和國際上的生命科學市場提供關鍵試劑。它的試劑使生物製藥產品的發現、開發和生產成為可能，如藥物療法、新型疫苗和分子診斷。該公司提供用於細胞生長和克隆的預先澆注的培養基板；用於細胞擴增的液體細胞培養液和補充劑；以及用於樣品處理、再懸浮和純化的分子生物試劑。它服務於生命科學市場，包括製藥和生物技術公司、合同開發和製造組織、體外診斷特許經營權以及學術和政府研究機構。該公司成立於1996年，總部設在加利福尼亞州霍利斯特。
About Navidea Biopharmaceuticals
關於Navidea生物製藥公司
(Get Rating)
(獲取評級)
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Navidea BiopPharmticals，Inc.是一家生物製藥公司，專注於精密免疫診斷藥物和免疫療法的開發和商業化。它通過兩個部分運作，即診斷物質和治療發展計劃。該公司開發的Manocept平臺針對激活的巨噬細胞上表達的CD206甘露糖受體，用於一系列診斷模式，包括單光子發射計算機斷層掃描、正電子發射斷層掃描、伽馬掃描、術中和/或光學熒光檢測，以及靶向巨噬細胞的治療化合物的輸送，以及免疫和炎症相關疾病。它開發的NAV3-31已經完成了IIb期臨牀試驗，以評估成像的重複性、再現性和穩定性，以及Tc99mtilmanocept成像用於治療中到重度類風濕性關節炎(RA)患者的抗腫瘤壞死因子α療法的能力；NAV3-35正在進行RA成像的IIb期臨牀試驗；NAV3-33正在進行RA的第三階段臨牀試驗；NAV3-32是RA相關關節的2b期試驗。該公司還在開發Tc99m替馬諾普，用於心血管、卡波西肉瘤、結核病和其他免疫治療應用。該公司前身為NeoProbe Corporation，並於2012年1月更名為Navidea生物製藥公司。Navidea生物製藥公司成立於1983年，總部設在俄亥俄州都柏林。
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.
接收阿爾法·特克諾瓦日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Alpha Tenowva和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。